Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 19245 | 449 | 27.8 | 74% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | NATEGLINIDE | Author keyword | 59 | 51% | 18% | 82 |
| 2 | KAD 1229 | Author keyword | 34 | 93% | 3% | 13 |
| 3 | REPAGLINIDE | Author keyword | 26 | 31% | 16% | 70 |
| 4 | A 4166 | Author keyword | 21 | 90% | 2% | 9 |
| 5 | PRANDIAL GLUCOSE REGULATION | Author keyword | 12 | 75% | 2% | 9 |
| 6 | MITIGLINIDE | Author keyword | 10 | 41% | 4% | 20 |
| 7 | BTS 67 582 | Author keyword | 8 | 75% | 1% | 6 |
| 8 | MEGLITINIDE ANALOGUE | Author keyword | 4 | 75% | 1% | 3 |
| 9 | PHARMACEUT REGULATORY AFFAIRS QUAL ASSURANCE DE | Address | 4 | 75% | 1% | 3 |
| 10 | CLONAL PANCREATIC BETA CELLS | Author keyword | 4 | 56% | 1% | 5 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | NATEGLINIDE | 59 | 51% | 18% | 82 | Search NATEGLINIDE | Search NATEGLINIDE |
| 2 | KAD 1229 | 34 | 93% | 3% | 13 | Search KAD+1229 | Search KAD+1229 |
| 3 | REPAGLINIDE | 26 | 31% | 16% | 70 | Search REPAGLINIDE | Search REPAGLINIDE |
| 4 | A 4166 | 21 | 90% | 2% | 9 | Search A+4166 | Search A+4166 |
| 5 | PRANDIAL GLUCOSE REGULATION | 12 | 75% | 2% | 9 | Search PRANDIAL+GLUCOSE+REGULATION | Search PRANDIAL+GLUCOSE+REGULATION |
| 6 | MITIGLINIDE | 10 | 41% | 4% | 20 | Search MITIGLINIDE | Search MITIGLINIDE |
| 7 | BTS 67 582 | 8 | 75% | 1% | 6 | Search BTS+67+582 | Search BTS+67+582 |
| 8 | MEGLITINIDE ANALOGUE | 4 | 75% | 1% | 3 | Search MEGLITINIDE+ANALOGUE | Search MEGLITINIDE+ANALOGUE |
| 9 | CLONAL PANCREATIC BETA CELLS | 4 | 56% | 1% | 5 | Search CLONAL+PANCREATIC+BETA+CELLS | Search CLONAL+PANCREATIC+BETA+CELLS |
| 10 | POTENT HYPOGLYCEMIC EFFECT | 3 | 100% | 1% | 3 | Search POTENT+HYPOGLYCEMIC+EFFECT | Search POTENT+HYPOGLYCEMIC+EFFECT |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | A 4166 | 42 | 73% | 7% | 32 |
| 2 | MEGLITINIDE ANALOGS | 27 | 83% | 3% | 15 |
| 3 | KAD 1229 | 18 | 83% | 2% | 10 |
| 4 | N TRANS 4 ISOPROPYLCYCLOHEXYL CARBONYL D PHENYLALANINE A 4166 | 18 | 89% | 2% | 8 |
| 5 | DERIVATIVE HYPOGLYCEMIC AGENT | 12 | 86% | 1% | 6 |
| 6 | HYPOGLYCEMIC AGENT | 11 | 28% | 7% | 33 |
| 7 | DIHYDRATE KAD 1229 | 11 | 100% | 1% | 6 |
| 8 | REPAGLINIDE | 11 | 25% | 8% | 36 |
| 9 | MEALTIME GLUCOSE REGULATION | 9 | 83% | 1% | 5 |
| 10 | PRANDIAL GLUCOSE REGULATION | 9 | 83% | 1% | 5 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| Repaglinide A Review of Its Use in Type 2 Diabetes Mellitus | 2012 | 20 | 74 | 55% |
| Meglitinide analogues: a review of clinical data focused on recent trials | 2006 | 29 | 50 | 78% |
| Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis | 2010 | 12 | 14 | 43% |
| Clinical pharmacokinetics and pharmacodynamics of repaglinide | 2002 | 73 | 32 | 50% |
| Clinical pharmacokinetics of nateglinide - A rapidly-absorbed, short-acting insulinotropic agent | 2004 | 58 | 54 | 52% |
| Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients | 2008 | 14 | 39 | 69% |
| Meglitinide analogues for type 2 diabetes mellitus (Review) | 2007 | 25 | 49 | 55% |
| Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers | 2004 | 43 | 28 | 43% |
| Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide | 2007 | 32 | 71 | 34% |
| Repaglinide - A pharmacoeconomic review of its use in type 2 diabetes mellitus | 2004 | 22 | 55 | 49% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | PHARMACEUT REGULATORY AFFAIRS QUAL ASSURANCE DE | 4 | 75% | 0.7% | 3 |
| 2 | QA RA PHARMACOVIGILANCE | 1 | 27% | 0.7% | 3 |
| 3 | BIOMET MED AFFAIRS | 1 | 50% | 0.2% | 1 |
| 4 | D CAMPANACCI CLIN MED PL BIOTECH | 1 | 50% | 0.2% | 1 |
| 5 | DRUG METAB PHARMACOKINETKAWASAKI KU | 1 | 50% | 0.2% | 1 |
| 6 | HUMANPHARMAKOL ZENTRUM | 1 | 50% | 0.2% | 1 |
| 7 | SRI VENKATESHWARA PHARM | 1 | 50% | 0.2% | 1 |
| 8 | STATE DURG | 1 | 50% | 0.2% | 1 |
| 9 | TTC IND AREAMIDC | 1 | 50% | 0.2% | 1 |
| 10 | UNITE ENDOCRINOL MALAD METAB | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000275293 | INTERMITTENT GLUCOSE//POSTPRANDIAL HYPERGLYCEMIA//GLYCEMIC VARIABILITY |
| 2 | 0.0000175368 | GLIMEPIRIDE//JTT 608//SECONDARY FAILURE |
| 3 | 0.0000170500 | METFORMIN HYDROCHLORIDE//PIOGLITAZONE HYDROCHLORIDE//ROSIGLITAZONE MALEATE |
| 4 | 0.0000141905 | D GLUCOSE METABOLISM//SUCCINIC ACID DIMETHYL ESTER//EXPT HORMONOL |
| 5 | 0.0000111511 | ACARBOSE//ALPHA GLUCOSIDASE INHIBITOR//MIGLITOL |
| 6 | 0.0000110810 | METFORMIN//LACTIC ACIDOSIS//METFORMIN ASSOCIATED LACTIC ACIDOSIS |
| 7 | 0.0000105447 | GLICLAZIDE//INTERNAL MED DIABETOL CLIN PHARMACOL//DRUG QUAL CONTROL PHARMACOVIGILANC |
| 8 | 0.0000104861 | A23187 CALCIUM IONOPHORE//BRANCHED ALKANOL//DIABETIC HYPERTENSIVE PATIENTS |
| 9 | 0.0000094641 | KIR62//ATP SENSITIVE K CHANNEL//SUR2A |
| 10 | 0.0000093044 | INSULIN GLARGINE//INSULIN DETEMIR//BIPHASIC INSULIN ASPART 30 |